LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Sage Therapeutics Inc

Gesloten

SectorGezondheidszorg

6.86 3.94

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

6.84

Max

6.92

Belangrijke statistieken

By Trading Economics

Inkomsten

34M

-62M

Verkoop

1.2M

14M

EPS

-0.998

Winstmarge

-442.395

Werknemers

353

EBITDA

13M

-67M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+27% upside

Dividenden

By Dow Jones

Volgende Winsten

30 jul 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-64M

423M

Vorige openingsprijs

2.92

Vorige sluitingsprijs

6.86

Nieuwssentiment

By Acuity

100%

0%

367 / 382 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Sage Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 mei 2025, 23:47 UTC

Marktinformatie

Nikkei May Trade Rangebound Amid Uncertainty Over U.S. Tariffs -- Market Talk

18 mei 2025, 23:40 UTC

Marktinformatie

Gold Rises Amid Concerns Over U.S. Fiscal Deficit -- Market Talk

18 mei 2025, 18:00 UTC

Winsten

Tax Bill News; Target, Home Depot, and Snowflake Earnings; and More Stock Market News to Watch This Week -- Barrons.com

18 mei 2025, 17:01 UTC

Top Nieuws

GM Is Fighting California on EVs. This Is What It Wants to Overturn and Why. -- Barrons.com

18 mei 2025, 16:20 UTC

Winsten

Tesla Demand Hasn't Rebounded Yet. Watch China This Week. -- Barrons.com

18 mei 2025, 12:09 UTC

Top Nieuws

Trump Sounds Upbeat on Ukraine Cease-Fire as Russia Unleashes Drone Barrage -- WSJ

17 mei 2025, 17:15 UTC

Top Nieuws

Trump Attacks Walmart for Tariff-Related Price Increases -- WSJ

17 mei 2025, 09:30 UTC

Top Nieuws
Winsten

In a Trade War, Walmart Lacks Some of Amazon's Ammunition -- Heard on the Street -- WSJ

17 mei 2025, 08:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

17 mei 2025, 08:20 UTC

Marktinformatie
Winsten

Financial Services Roundup: Market Talk

16 mei 2025, 23:18 UTC

Top Nieuws

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

16 mei 2025, 22:30 UTC

Top Nieuws

U.S. Loses Last Triple-A Credit Rating -- Update

16 mei 2025, 21:56 UTC

Marktinformatie

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

16 mei 2025, 21:56 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

16 mei 2025, 21:54 UTC

Top Nieuws

U.S. Loses Last Triple-A Credit Rating -- WSJ

16 mei 2025, 21:22 UTC

Marktinformatie

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

16 mei 2025, 21:17 UTC

Marktinformatie

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

16 mei 2025, 21:17 UTC

Top Nieuws

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

16 mei 2025, 21:05 UTC

Marktinformatie

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

16 mei 2025, 20:55 UTC

Acquisities, Fusies, Overnames

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 mei 2025, 20:50 UTC

Marktinformatie
Winsten

Financial Services Roundup: Market Talk

16 mei 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

16 mei 2025, 20:37 UTC

Top Nieuws

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

16 mei 2025, 20:33 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

16 mei 2025, 20:30 UTC

Acquisities, Fusies, Overnames

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

16 mei 2025, 20:18 UTC

Top Nieuws

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

16 mei 2025, 20:16 UTC

Top Nieuws

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

16 mei 2025, 20:15 UTC

Winsten

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

16 mei 2025, 20:11 UTC

Acquisities, Fusies, Overnames

Henry Schein: William K. Daniel Joins Board

16 mei 2025, 20:10 UTC

Acquisities, Fusies, Overnames

Henry Schein: Strategic Investment by KKR Completed

Peer Vergelijking

Prijswijziging

Sage Therapeutics Inc Prognose

Koersdoel

By TipRanks

27% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 8.75 USD  27%

Hoogste 12 USD

Laagste 5 USD

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor Sage Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

14 ratings

2

Buy

11

Hold

1

Sell

Technische score

By Trading Central

N/A / 7.285Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Neutral Evidence

Lange Termijn

Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Sage Therapeutics Inc

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.